Citat:
Här är en artikel som visar att man får B- och T-minnesceller.Jag hoppas att det ni säger stämmer. Och att jag därigenom har massor av robusta hungriga t-celler.
Dock, kom det ju fram redan i våras att Sars-2 "äter" t-celler.
Saundras artikelfyllda tråd: (FB) Coronatillfrisknade löper ökad risk för ännu svårare symtom vid återinfektion
Dräller tyvärr av artiklar som visar på farliga/farligare återinfektioner.
Man bör ju ställa sig frågan om vaccin i själva verket kommer förvärra situationen?
På samma sätt som överdriven användning av antibiotika bara ger värre bakterier?!
Allt man gör går ju emot vedertagen kunskap!
Dock, kom det ju fram redan i våras att Sars-2 "äter" t-celler.
Saundras artikelfyllda tråd: (FB) Coronatillfrisknade löper ökad risk för ännu svårare symtom vid återinfektion
Dräller tyvärr av artiklar som visar på farliga/farligare återinfektioner.
Man bör ju ställa sig frågan om vaccin i själva verket kommer förvärra situationen?
På samma sätt som överdriven användning av antibiotika bara ger värre bakterier?!
Allt man gör går ju emot vedertagen kunskap!
(Min fetning.)
Citat:
The emergence of adaptive immunity in response to the novel Betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), occurs within the first 7 to 10 days of infection.1-3 Understanding the key features and evolution of B-cell– and T-cell–mediated adaptive immunity to SARS-CoV-2 is essential in forecasting coronavirus disease 2019 (COVID-19) outcomes and for developing effective strategies to control the pandemic. Ascertaining long-term B-cell and T-cell immunological memory against SARS-CoV-2 is also critical to understanding durable protection.
A robust memory B-cell and plasmablast expansion is detected early in infection,2,4 with secretion of serum IgM and IgA antibodies by day 5 to 7 and IgG by day 7 to 10 from the onset of symptoms. In general, serum IgM and IgA titers decline after approximately 28 days (Figure), and IgG titers peak at approximately 49 days. Simultaneously, SARS-CoV-2 activates T cells in the first week of infection, and virus-specific memory CD4+ cells and CD8+ T cells reportedly peak within 2 weeks but remain detectable at lower levels for 100 or more days of observation. Grifoni et al1 and others5,6 have identified SARS-CoV-2–specific memory CD4+ T cells in up to 100% and CD8+ T cells in approximately 70% of patients recovering from COVID-19. Although severe COVID-19 is characterized by high-viral titers, dysregulated innate inflammatory cytokine and chemokine responses and prolonged lymphopenia, antibody-dependent enhancement or dominant CD4+ TH2-type cytokines (eg, IL-4, IL-5, IL-13) do not appear to contribute to acute COVID-19 severity.
A robust memory B-cell and plasmablast expansion is detected early in infection,2,4 with secretion of serum IgM and IgA antibodies by day 5 to 7 and IgG by day 7 to 10 from the onset of symptoms. In general, serum IgM and IgA titers decline after approximately 28 days (Figure), and IgG titers peak at approximately 49 days. Simultaneously, SARS-CoV-2 activates T cells in the first week of infection, and virus-specific memory CD4+ cells and CD8+ T cells reportedly peak within 2 weeks but remain detectable at lower levels for 100 or more days of observation. Grifoni et al1 and others5,6 have identified SARS-CoV-2–specific memory CD4+ T cells in up to 100% and CD8+ T cells in approximately 70% of patients recovering from COVID-19. Although severe COVID-19 is characterized by high-viral titers, dysregulated innate inflammatory cytokine and chemokine responses and prolonged lymphopenia, antibody-dependent enhancement or dominant CD4+ TH2-type cytokines (eg, IL-4, IL-5, IL-13) do not appear to contribute to acute COVID-19 severity.